Amgen says it expects pandemic to limit sales through 2021 933thedrive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 933thedrive.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca, Amgen Report Positive Tezepelumab Study Results
Fri, 26th Feb 2021 14:27
(Alliance News) - AstraZeneca PLC and Amgen Inc on Friday said positive full results from the Navigator phase III trial of tezepelumab showed a reduction in the annualised asthma exacerbation rate in severe, uncontrolled asthma patients.
Tezepelumab blocks the action of thymic stromal lymphopoietin, an epithelial cytokine that plays a key role across the spectrum of asthma inflammation.
The Cambridge, England-based biopharmaceutical company also said tezepelumab demonstrated statistically significant improvements in every key secondary endpoint compared to placebo. These are ground-breaking results for the many patients with severe asthma who continue to face debilitating symptoms despite receiving standard of care inhaled medicines and currently approved biologics, said Andrew Menzies-Gow, director of the Lung Division, Royal Brompton Hospital, London, and principal investigator of the Navi
Astrazeneca News Headlines AZN Share News Financial News Articles for Astrazeneca Plc Ord Shs $0 25 updated throughout the day lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.
3 Min Read
(Reuters) - U.S. biotech Amgen Inc on Tuesday provided a 2021 earnings forecast below Wall Street estimates and said it had paused or halted enrollment for clinical trials of three cancer drugs.
Slideshow ( 2 images )
The company also said it expects net selling prices for its drugs to fall by a rate in the mid-single digits this year - after a drop of 6% in 2020 - and the COVID pandemic will continue to impact sales.
Amgen shares, which closed at $240.49, were down $4.37, or 2%, at $236.12 after hours.
For 2021, Amgen forecast adjusted earnings of $16.00 to $17.00 per share, putting the midpoint below analysts’ estimates of $17.03 per share, according to IBES data from Refinitiv. The full-year revenue forecast of $25.8 billion to $26.6 billion was more in line with analyst projections of $26.45 billion.
Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment, technology, video and pictures.